Shaji Kumar, MD
Enriched profileConsultant, Division of Hematology; Mark and Judy Mullins Professor of Hematological Malignancies; Professor of Medicine, College of Medicine and Science · Mayo Clinic
Shaji Kumar is Consultant, Division of Hematology; Mark and Judy Mullins Professor of Hematological Malignancies; Professor of Medicine, College of Medicine and Science at Mayo Clinic. OpenAlex indexes 2,207 publications with 95,766 citations (h-index 137); ClinicalTrials.gov lists 40 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology profiles in the findmyKOL directory. Clarivate lists Shaji Kumar as a Highly Cited Researcher (Clinical Medicine, 2019-2024; Cross-Field, 2018).
Data verified 25 Aug 2026
Overview
Updated 13 Oct 2026
Shaji Kumar, M.D., is Consultant, Division of Hematology at Mayo Clinic, Rochester, Minnesota, Division of Hematology, Department of Medicine. The public record shows 2,207 publications with 95,766 citations (h-index 137), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Amyloidosis: Diagnosis, Treatment, Outcomes. It also documents an investigator role on 40 registered clinical trials, industry payments reported by 29 companies, 4 NIH-funded awards (2012–2026).
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Multiple Myeloma Research and Treatments
- 40 registered trials on ClinicalTrials.gov
- Open Payments reporting from 29 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 377 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 899.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 40 registered studies on ClinicalTrials.gov. The most recent:
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Industry payments
Updated 13 Oct 2026
29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
- Celltrion, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.1%Thalidomide Analog44.1%Revlimid57%Lenalidomide43%Part D<11 patientsDermatology
39.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor39.7%Acyclovir100%Part D<11 patientsAnti-infectives
16.2%Short-acting sulfonamides16.2%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
4 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Impact of Genetic susceptibility along the continuum from MGUS to MM
Mayo Clinic Rochester
FY2026$617,059U01CA271014 - Impact of Genetic susceptibility along the continuum from MGUS to MM
Mayo Clinic Rochester
FY2025$659,222U01CA271014 - Impact of Genetic susceptibility along the continuum from MGUS to MM
Mayo Clinic Rochester
FY2024$621,962U01CA271014
Congress activity
Updated 13 Oct 2026
449 congress contributions (2006–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 3180: CAR-T in high-risk plasma cell dyscrasias: A systematic review of AL amyloidosis and plasma cell leukemia
AACR Annual Meeting
AACR2025Co-author - Abstract 4917: The association between MGUS and CHIP and their impact on multiple myeloma
AACR Annual Meeting
AACR2025Co-author - Association of immune cell subsets and cytokine profiles with immune-related hyperinflammatory states after CAR T-cell therapy.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Shaji-Kumar
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/myelomamd
Mentions by others
where others cite or feature them- Hematology.org
Active on X/Twitter as @myelomaMD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hematology.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board Certified
American Board of Internal Medicine: Internal Medicine (1999–present), Hematology (2004–present), Medical Oncology
2004verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - M.D.
All India Institute of Medical Sciences, New Delhi, India
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗ - Internal medicine residency
All India Institute of Medical Sciences; internal medicine residency and hematology/oncology fellowship, Mayo Graduate School of Medicine, Rochester, MN; Mayo Foundation Scholar …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
Editorial & leadership roles
journal and society appointments- Editor-in-Chief
The Hematologist: ASH News and Reports (American Society of Hematology), 2023-2025
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hematology.org ↗ - Vice President
International Myeloma Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Chair
NCCN (National Comprehensive Cancer Network) Multiple Myeloma Guidelines Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Co-Chair
NCI Myeloma Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Medical Director
Mayo Clinic Cancer Center Clinical Trials/Research Office
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Chair
Myeloma, Amyloidosis and Dysproteinemia Disease Group, Mayo Clinic
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗ - Research Chair
Division of Hematology; Associate Chair for Research, Department of Medicine, Mayo Clinic
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Associate Editor
American Journal of Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hematology.org ↗ - Member
Scientific Advisory Board, International Myeloma Foundation (IMF); member, International Myeloma Working Group (IMWG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myeloma.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine201920202021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- 2024 Robert A. Kyle Lifetime Achievement Award (International Myeloma Working Group / IMWG Summit, Madrid)
recognized for leading development of IMWG response criteria and MRD definitions in myeloma
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myeloma.org ↗ - 2021 Brian G.M. Durie Outstanding Achievement Award (International Myeloma Foundation)
for excellence in myeloma research
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗
Secondary affiliations
appointments beyond the home institution- Mayo Foundation Scholar
Dana-Farber Cancer Institute, Boston, MA (postdoctoral training)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Editorial board member
touchONCOLOGY
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →touchoncology.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hematology.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myeloma.org ↗
- HealthTree Podcast for Multiple Myeloma
interview with Dr. Shaji Kumar (Mayo Clinic) on ETBs / novel inhibitors in myeloma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - Medscape Myeloma Podcast Series
"The Future of Multiple Myeloma" featuring Dr. Shaji Kumar
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medscape.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
Ayalew Tefferi, MD
Mayo Clinic
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens